Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(145 products)
- Bcr-Abl(102 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(170 products)
- JAK(245 products)
- PDGFR(126 products)
- RAAS(86 products)
- Src(78 products)
- Syk(38 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(268 products)
Show 6 more subcategories
Found 1414 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
FM-479
CAS:<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Formula:C25H26N6O2Purity:98%Color and Shape:SolidMolecular weight:442.523TAK-659
CAS:<p>TAK-659 is a spleen tyrosine kinase (SYK) inhibitor.</p>Formula:C17H21FN6OPurity:98%Color and Shape:SolidMolecular weight:344.39Famitinib malate
CAS:<p>Famitinib malate (SHR1020) is a potent oral kinase inhibitor targeting c-kit, VEGFR-2, and PDGFRβ, with IC50s 2.3, 4.7, 6.6 nM, useful for cancer research.</p>Formula:C27H33FN4O7Color and Shape:SolidMolecular weight:544.57Upadacitinib tartrate
CAS:<p>Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.</p>Formula:C21H33F3N6O11Purity:98%Color and Shape:SolidMolecular weight:602.521PF-06459988
CAS:<p>PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.</p>Formula:C19H22ClN7O3Purity:98%Color and Shape:SolidMolecular weight:431.88Roslin 2 bromide
CAS:<p>Roslin 2 bromide (Benzylhexamethylenetetramine bromide) is a p53 reactivator that disrupts the binding of FAK and p5.</p>Formula:C13H19BrN4Purity:99.34%Color and Shape:SolidMolecular weight:311.22PF-303
CAS:<p>PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.</p>Formula:C22H21ClN6O2Color and Shape:SolidMolecular weight:436.89JAK-IN-24
CAS:<p>JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.</p>Formula:C20H25N5O2Color and Shape:SolidMolecular weight:367.44JNJ-17029259
CAS:<p>JNJ-17029259 is an orally selective, potent inhibitors of the vascular endothelial growth factor receptor-2 (VEGF-R2).</p>Formula:C26H30N6OPurity:98%Color and Shape:SolidMolecular weight:442.56Brolucizumab
CAS:<p>Brolucizumab (anti-VEGF-A scFv) potently blocks VEGF-A to reduce neovascularization in wet AMD, with picomolar binding affinity.</p>Purity:95%Color and Shape:LiquidEGFR-IN-29
CAS:<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Formula:C36H46BrN8O2PColor and Shape:SolidMolecular weight:733.68Atiprimod dimaleate
CAS:<p>Atiprimod Dimaleate is a JAK2 inhibitor.</p>Formula:C30H52N2O8Color and Shape:SolidMolecular weight:568.74BMS-599626 Hydrochloride
CAS:<p>BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.</p>Formula:C27H28ClFN8O3Purity:99.98%Color and Shape:SolidMolecular weight:567.01ALK/EGFR-IN-1
CAS:<p>ALK/EGFR-IN-1 (Compound 8l) is a dual inhibitor targeting both ALK and EGFR, effectively blocking their phosphorylation.</p>Formula:C27H34ClN7O3SPurity:98%Color and Shape:SolidMolecular weight:572.12Simotinib
CAS:<p>Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.</p>Formula:C25H26ClFN4O4Purity:99.7%Color and Shape:SolidMolecular weight:500.95TCJL37
CAS:<p>TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.</p>Formula:C17H11ClF2N4O2Color and Shape:SolidMolecular weight:376.74SNIPER(TACC3)-11
CAS:<p>SNIPER(TACC3)-11 is a powerful FGFR3-TACC3 protein degrader, reducing its amount and hindering FGFR3-TACC3+ cancer cell growth.</p>Formula:C51H66N10O7S2Color and Shape:SolidMolecular weight:995.26SD 1008
CAS:<p>SD 1008 is a JAK2/STAT3 signaling pathway inhibitor. SD 1008 inhibits activation of STAT3, JAK2, and Src.</p>Formula:C18H19NO5Purity:98%Color and Shape:SolidMolecular weight:329.35Lepzacitinib
CAS:<p>Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.</p>Formula:C18H21N5O3Purity:99.85%Color and Shape:SolidMolecular weight:355.39DZD1516
CAS:<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Formula:C28H27F2N7O3Purity:98%Color and Shape:SolidMolecular weight:547.56Itacnosertib (hydrocholide)
CAS:<p>Itacnosertib hydrochloride acts as an inhibitor targeting JAK2, ACVR1 (ALK2), and ALK5 [1].</p>Formula:C26H29ClN8OColor and Shape:SolidMolecular weight:505.01BTK-IN-19
CAS:<p>BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM .</p>Formula:C21H22Cl2N6OColor and Shape:SolidMolecular weight:445.35UNC4203
CAS:<p>UNC4203 inhibits MERTK (1.2 nM), AXL (140 nM), TYRO3 (42 nM), FLT3 (90 nM); potent, selective, oral.</p>Formula:C30H44N6OColor and Shape:SolidMolecular weight:504.71DW10075
CAS:<p>DW10075, a novel potent and highly selective inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.</p>Formula:C29H23N5O3Color and Shape:SolidMolecular weight:489.52(Rac)-PF-06250112
CAS:<p>(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.</p>Formula:C22H20F2N6O2Purity:98%Color and Shape:SolidMolecular weight:438.43HDAC/JAK/BRD4-IN-1
CAS:<p>HDAC/JAK/BRD4-IN-1 (compound 25ap) is a potent triple inhibitor targeting HDAC, JAK, and BRD4.</p>Formula:C24H28N6O3Purity:98%Color and Shape:SolidMolecular weight:448.52MTP
CAS:<p>MTP, a PKM2 inhibitor, promotes apoptosis in cancer cells via caspase-3 activation while also inducing autophagy and enhancing ROS generation.</p>Formula:C29H23F3N4O2Purity:98%Color and Shape:SolidMolecular weight:516.51BPIQ-I
CAS:<p>BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.</p>Formula:C16H12BrN5Color and Shape:SolidMolecular weight:354.2EGFR-IN-36
CAS:<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Formula:C26H25ClN6O2Color and Shape:SolidMolecular weight:488.97ALK/EGFR-IN-3
CAS:<p>ALK/EGFR-IN-3 is a dual ALK and EGFR inhibitor that demonstrates potent anti-proliferative effects on various cancer cell lines, including H1975, PC9, and Baf3-</p>Formula:C27H34ClN7O3SColor and Shape:SolidMolecular weight:572.12EGFR-IN-74
<p>EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.</p>Formula:C32H28BrF3N6O4SColor and Shape:SolidMolecular weight:729.57SG3-179
CAS:<p>SG3-179 is a BET inhibitor.</p>Formula:C28H35ClFN7O3SColor and Shape:SolidMolecular weight:604.14Pivanex
CAS:<p>Pivanex, an oral HDAC inhibitor, targets metastasis, angiogenesis, reduces Bcr-Abl protein, and promotes apoptosis.</p>Formula:C10H18O4Purity:≥98%Color and Shape:SolidMolecular weight:202.25FLT3/ITD-IN-4
CAS:<p>FLT3/ITD-IN-4 inhibits FLT3-ITD mutations in acute myeloid leukemia (IC50: 2.3 nM).</p>Formula:C25H22N4O5Color and Shape:SolidMolecular weight:458.47YS-363
CAS:<p>YS-363 is a potent, selective, and orally active inhibitor of the epidermal growth factor receptor (EGFR), exhibiting half-maximal inhibitory concentrations (</p>Formula:C30H30N4O3Purity:98%Color and Shape:SolidMolecular weight:494.58T338C Src-IN-1
CAS:<p>T338C Src-IN-1 is a potent mutant-Src T338C inhibitor(T338C,IC50=111 nM relative to WT c-Src (10-fold increase)).</p>Formula:C17H20N6O2SPurity:98%Color and Shape:SolidMolecular weight:372.44JAK-IN-1
CAS:<p>JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.</p>Formula:C20H24N6O2Purity:98%Color and Shape:SolidMolecular weight:380.44MET kinase-IN-3
CAS:<p>MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.</p>Formula:C25H16ClF2N5O2Color and Shape:SolidMolecular weight:491.88ALK-IN-6
CAS:<p>ALK-IN-6 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK, IC50s: 71 nM, 18.72 nM, and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L).</p>Formula:C26H29ClD3N5O3SPurity:98%Color and Shape:SolidMolecular weight:533.1UNC5293
CAS:<p>UNC5293: potent oral MERTK inhibitor, Ki=190 pM, IC50=0.9 nM; selective vs Axl/Tyro3/Flt3; good mouse PK; used in leukemia research.</p>Formula:C30H42N6O2Color and Shape:SolidMolecular weight:518.69PAT-505
CAS:<p>PAT-505 is an autologous epidermal growth factor inhibitor.</p>Formula:C23H18ClF2N3O2SPurity:98.84%Color and Shape:SolidMolecular weight:473.92TIE-2/VEGFR-2 kinase-IN-3
CAS:<p>TIE-2/VEGFR-2 kinase-IN-3, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting IC50 values</p>Formula:C23H17F4N5O3SColor and Shape:SolidMolecular weight:519.47Tyk2-IN-9
CAS:<p>Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.</p>Formula:C20H17N9Purity:98%Color and Shape:SolidMolecular weight:383.41Tubulin/JAK2-IN-1
CAS:<p>Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significant</p>Formula:C22H20N6O3Color and Shape:SolidMolecular weight:416.43JAK-IN-25
CAS:<p>JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.</p>Formula:C19H17N5O4Purity:98%Color and Shape:SolidMolecular weight:379.37KB SRC 4
CAS:<p>KB SRC 4 is a selective and potent c-Src inhibitor with antitumour activity that inhibits the growth of cancer cells.CAS 번호13460-73-83-4</p>Formula:C32H23ClN8Purity:98.83% - 99.34%Color and Shape:SolidMolecular weight:555.03JAK-IN-17
<p>"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."</p>Formula:C33H38F2N6O8Color and Shape:SolidMolecular weight:684.69Sevabertinib
CAS:<p>Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.</p>Formula:C24H25ClN4O5Purity:99.81%Color and Shape:SolidMolecular weight:484.93BMS-935177
CAS:<p>BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.</p>Formula:C31H26N4O3Purity:99.89%Color and Shape:SolidMolecular weight:502.56Zongertinib
CAS:<p>Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (</p>Formula:C29H29N9O2Purity:98.24%Color and Shape:SolidMolecular weight:535.6
